Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with CHOP chemotherapy in the rituximab era

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33144645" target="_blank" >RIV/61989592:15110/14:33144645 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.3109/10428194.2013.850167" target="_blank" >http://dx.doi.org/10.3109/10428194.2013.850167</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/10428194.2013.850167" target="_blank" >10.3109/10428194.2013.850167</a>

Result language

angličtina

Original language name

Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with CHOP chemotherapy in the rituximab era

Original language description

Abstract This study analyzed the prognostic significance of sIL-2Ralfa levels in 100 prospectively enrolled patients with previously untreated follicular lymphoma. It showed that sIL-2Ralfa level ? 115 pmol/L at the time of treatment initiation correlates with the high FLIPI-2, bulky disease, advanced clinical stage, number of involved lymph nodes, bone marrow involvement and elevated beta-2 microglobulin (B2M) level. When testing all patients, sIL-2Ralfa ? 115 pmol/L was associated with significantly shorter progression-free (PFS; p{0.03, HR 2.04) but not overall (OS; p=0.06, HR 2.36) survival rates. Subanalysis of the CHOP+-rituximab patients showed higher predictive power for both PFS (HR 2.75, 95% CI 1.24-6.11, p=0.01,) and OS (HR 3.33, 95% CI 1.15-9.63, p=0.02,). In the whole population (n=100), only B2M proved a significant univariate predictor (p=0.007, HR = 2.8) of the PFS. When testing patients treated with CHOP+-rituximab, sIL-2Ralfa was found to be the best univariate predic

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

S - Specificky vyzkum na vysokych skolach

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia & Lymphoma

ISSN

1042-8194

e-ISSN

—

Volume of the periodical

55

Issue of the periodical within the volume

7

Country of publishing house

GB - UNITED KINGDOM

Number of pages

7

Pages from-to

1584-1590

UT code for WoS article

—

EID of the result in the Scopus database

—